These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20497167)

  • 1. Uninformed consent: mass screening for prostate cancer.
    Justman S
    Bioethics; 2012 Mar; 26(3):143-8. PubMed ID: 20497167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of informed consent on patient interest in prostate-specific antigen screening.
    Wolf AM; Nasser JF; Wolf AM; Schorling JB
    Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen testing to screen for prostate cancer.
    Budenholzer BR
    J Fam Pract; 1995 Sep; 41(3):270-8. PubMed ID: 7544400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer in 2006: PSA in the 21st century.
    Maroni PD; Crawford ED
    N C Med J; 2006; 67(2):136-9. PubMed ID: 16752718
    [No Abstract]   [Full Text] [Related]  

  • 8. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
    Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
    Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
    Albertsen PC
    Acta Oncol; 2005; 44(3):255-64. PubMed ID: 16076698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].
    Bonneux L
    Ned Tijdschr Geneeskd; 2005 Apr; 149(18):966-71. PubMed ID: 15903036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening: clinical applications and challenges.
    Brawley OW
    Urol Oncol; 2004; 22(4):353-7. PubMed ID: 15283896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer screening: a place for informed consent?
    Glodé LM
    Hosp Pract (Off Ed); 1994 Sep; 29(9):8, 11-2. PubMed ID: 7521881
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen screening: friend or foe?
    Linn MM; Ball RA; Maradiegue A
    Urol Nurs; 2007 Dec; 27(6):481-9; quiz 490. PubMed ID: 18217530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients?
    Wolf AM; Philbrick JT; Schorling JB
    Am J Med; 1997 Oct; 103(4):308-14. PubMed ID: 9382123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
    van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
    Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public awareness of prostate cancer and the prostate-specific antigen test.
    Mainous AG; Hagen MD
    Cancer Pract; 1994; 2(3):217-21. PubMed ID: 7519944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.